Answer
With gilteritinib fumarate, diarrhoea, nausea and constipation are very common (≥1 in 10), occurring in 35.1%, 29.8% and 28.2%, respectively, among 319 patients with relapsed or refractory AML who received at least one 120 mg dose.
Sources for this answer
- Gilteritinib Astellas 40 mg film-coated tabletsAstellas Pharma Ltd · emc · SmPC §4.8 Undesirable effects · Version 7Document updated
Sources checked